Table 1.
Antiproliferative activity in vitro for samples of pure CQD, CQD@Arg, and CQD@Gly presented as IC50 values (μg/mL) ± standard deviation. Results from experiments carried out on human fibroblasts HFF-1 are presented for each biological replicate separately, while results for tumour cell lines are presented as means from three consecutive experiments.
| Sample | Cell Line IC50 (µg/mL) 1 | |||||
|---|---|---|---|---|---|---|
| HepG2 | CFPAC-1 | MCF-7 | HCT-116 | HFF-1 | ||
| Pure CQD | >100 | >100 | >100 | >100 | 1st experiment | 20.59 ± 0.02 |
| 2nd experiment | 1.50 ± 0.02 | |||||
| 3rd experiment | >100 | |||||
| CQD@Arg | >100 | >100 | >100 | >100 | 1st experiment | 7.85 ± 0.02 |
| 2nd experiment | Proliferative effect | |||||
| 3rd experiment | >100 | |||||
| CQD@Gly | >100 | 6.91 ± 0.81 | >100 | >100 | 1st experiment | 0.46 ± 0.01 |
| 2nd experiment | Proliferative effect | |||||
| 3rd experiment | >100 | |||||
1 IC50; 50% inhibitory concentration, or compound concentration required to inhibit tumour cell proliferation by 50%.